| Dr Bailey Camille Buck, DO | |
|
1585 W Liberty Rd, Atoka, OK 74525-1702 | |
| (580) 889-1981 | |
| Not Available |
| Full Name | Dr Bailey Camille Buck |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 4 Years |
| Location | 1585 W Liberty Rd, Atoka, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457978934 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 7381 (Oklahoma) | Primary |
| 207Q00000X | Family Medicine | 0345R (Oklahoma) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mays Housecall Home Health Of Durant | Durant, OK | Home health agency |
| Choctaw Nation Health Services Authority | Talihina, OK | Hospital |
| Alliancehealth Durant | Durant, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nes Oklahoma, Inc. | 1456264324 | 69 |
| Choctaw Nation Of Oklahoma | 1759294838 | 204 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).
Genentech, Inc., a wholly-owned member of the Roche Group, today announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections.
Every year, more than 100,000 Americans will need a life-saving organ transplant, yet in 2011 fewer than 22,000 transplants took place in the United States. In New York only 18 percent of New Yorkers who are eligible to donate are registered as organ donors, in stark contrast to the national average of 42 percent.
› Verified 3 days ago
| Entity Name | Nes Oklahoma, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528040722 PECOS PAC ID: 1456264324 Enrollment ID: O20040726000516 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).
Genentech, Inc., a wholly-owned member of the Roche Group, today announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections.
Every year, more than 100,000 Americans will need a life-saving organ transplant, yet in 2011 fewer than 22,000 transplants took place in the United States. In New York only 18 percent of New Yorkers who are eligible to donate are registered as organ donors, in stark contrast to the national average of 42 percent.
› Verified 3 days ago
| Entity Name | Arbuckle Memorial Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1700869492 PECOS PAC ID: 0840104956 Enrollment ID: O20061104000275 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).
Genentech, Inc., a wholly-owned member of the Roche Group, today announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections.
Every year, more than 100,000 Americans will need a life-saving organ transplant, yet in 2011 fewer than 22,000 transplants took place in the United States. In New York only 18 percent of New Yorkers who are eligible to donate are registered as organ donors, in stark contrast to the national average of 42 percent.
› Verified 3 days ago
| Entity Name | Oklahoma Emergency Physician Partners Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891039764 PECOS PAC ID: 0345493649 Enrollment ID: O20130118000115 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).
Genentech, Inc., a wholly-owned member of the Roche Group, today announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections.
Every year, more than 100,000 Americans will need a life-saving organ transplant, yet in 2011 fewer than 22,000 transplants took place in the United States. In New York only 18 percent of New Yorkers who are eligible to donate are registered as organ donors, in stark contrast to the national average of 42 percent.
› Verified 3 days ago
| Entity Name | Ess Of Sallisaw, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215431069 PECOS PAC ID: 6002170578 Enrollment ID: O20180509000869 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).
Genentech, Inc., a wholly-owned member of the Roche Group, today announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections.
Every year, more than 100,000 Americans will need a life-saving organ transplant, yet in 2011 fewer than 22,000 transplants took place in the United States. In New York only 18 percent of New Yorkers who are eligible to donate are registered as organ donors, in stark contrast to the national average of 42 percent.
› Verified 3 days ago
| Entity Name | Ess Of Stilwell, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497302566 PECOS PAC ID: 8527398940 Enrollment ID: O20190927002257 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).
Genentech, Inc., a wholly-owned member of the Roche Group, today announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections.
Every year, more than 100,000 Americans will need a life-saving organ transplant, yet in 2011 fewer than 22,000 transplants took place in the United States. In New York only 18 percent of New Yorkers who are eligible to donate are registered as organ donors, in stark contrast to the national average of 42 percent.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bailey Camille Buck, DO 5438 Barn Owl Dr, Durant, OK 74701-4784 Ph: (580) 677-2648 | Dr Bailey Camille Buck, DO 1585 W Liberty Rd, Atoka, OK 74525-1702 Ph: (580) 889-1981 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2010. The Company's partner, Auxilium Pharmaceuticals, Inc. markets XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.
New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001).
Genentech, Inc., a wholly-owned member of the Roche Group, today announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections.
Every year, more than 100,000 Americans will need a life-saving organ transplant, yet in 2011 fewer than 22,000 transplants took place in the United States. In New York only 18 percent of New Yorkers who are eligible to donate are registered as organ donors, in stark contrast to the national average of 42 percent.
› Verified 3 days ago
Dr. Joaquin Mauricio Forbes, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1201 W Liberty Rd, Atoka, OK 74525 Phone: 580-889-1981 Fax: 580-889-4009 | |
Ardry Lance Yarbrough, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1504 S Virginia Ave, Atoka, OK 74525 Phone: 580-889-4746 Fax: 580-889-4735 | |
Noel W. Emerson, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1510 S Virginia Ave, Atoka, OK 74525 Phone: 580-889-6621 Fax: 580-889-3602 |